<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597036</url>
  </required_header>
  <id_info>
    <org_study_id>15580</org_study_id>
    <secondary_id>I7W-MC-JQBA</secondary_id>
    <secondary_id>2015-001204-64</secondary_id>
    <nct_id>NCT02597036</nct_id>
  </id_info>
  <brief_title>A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of LY3127804 as Monotherapy and in Combination With Ramucirumab in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of the study drug known as LY3127804
      given as monotherapy and in combination with Ramucirumab for participants with advanced or
      metastatic solid tumors. The study will also include a safety exploration for the combination
      of LY3127804 plus ramucirumab and paclitaxel
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Actual">November 23, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline through Cycle 1 (28 Day Cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Dose (MTD) of LY3127804 Monotherapy and in Combination with Ramuricumab +/- Paclitaxel</measure>
    <time_frame>Baseline through Cycle 1 (28 Day Cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of LY3127804</measure>
    <time_frame>Cycle 1 Pre-Dose through 30 Days After Last Dose of Study Drug (Estimated up to 4 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC of Ramucirumab in Combination with LY3127804 +/- Paclitaxel</measure>
    <time_frame>Cycle 1 Pre-Dose through 30 Days After Last Dose of Study Drug (Estimated up to 4 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-LY3127804 Antibodies</measure>
    <time_frame>Cycle 1 Pre-Dose through 30 Days After Last Dose of Study Drug (Estimated up to 5 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Ramucirumab Antibodies</measure>
    <time_frame>Cycle 1 Pre-Dose through 30 Days After Last Dose of Study Drug (Estimated up to 5 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]</measure>
    <time_frame>Baseline through Measured Progressive Disease or Death (Estimated up to 4 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Measured Progressive Disease or Death (Estimated up to 4 Months)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part A LY3127804</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of LY3127804 given intravenously (IV) every 2 weeks (Q2W) for 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B LY3127804 + Ramucirumab Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C LY3127804 + Ramucirumab Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D LY3127804 + Ramucirumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3127804 and Ramucirumab given IV Q2W until participant qualifies for study discontinuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E LY3127804 + Ramucirumab + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3127804 and Ramucirumab given IV Q2W and Paclitaxel given IV on day 1, 8, and 15 until participant qualifies for study discontinuation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3127804</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Part A LY3127804</arm_group_label>
    <arm_group_label>Part B LY3127804 + Ramucirumab Dose 1</arm_group_label>
    <arm_group_label>Part C LY3127804 + Ramucirumab Dose 2</arm_group_label>
    <arm_group_label>Part D LY3127804 + Ramucirumab</arm_group_label>
    <arm_group_label>Part E LY3127804 + Ramucirumab + Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Part B LY3127804 + Ramucirumab Dose 1</arm_group_label>
    <arm_group_label>Part C LY3127804 + Ramucirumab Dose 2</arm_group_label>
    <arm_group_label>Part D LY3127804 + Ramucirumab</arm_group_label>
    <arm_group_label>Part E LY3127804 + Ramucirumab + Paclitaxel</arm_group_label>
    <other_name>LY3009806</other_name>
    <other_name>Cyramza</other_name>
    <other_name>1121B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Part E LY3127804 + Ramucirumab + Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of cancer that is advanced and/or metastatic.

          -  Have disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST )
             version 1.1.

          -  Have adequate organ function.

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Have discontinued previous treatments for cancer for at least 28 days or 5 half-lives
             prior to study enrolment.

        Exclusion Criteria:

          -  Have serious preexisting medical conditions.

          -  Have received treatment with a drug predominantly targeting Ang2 activity.

          -  Have symptomatic central nervous system (CNS) malignancy or metastasis.

          -  Have current hematologic malignancies.

          -  Have an active fungal, bacterial, and/or known viral infection.

          -  Have a corrected QT interval using Fridericia's correction (QTcF) of &gt;470 msec on
             screening electrocardiogram (ECG) at several consecutive days of assessment.

          -  Have a known sensitivity to mAbs or other therapeutic proteins.

          -  Have a history of hypertensive crisis or hypertensive encephalopathy or current poorly
             controlled hypertension despite standard medical management.

          -  Have a significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode
             within 3 months prior to receiving treatment.

          -  Receive anticoagulation therapy at therapeutic dose.

          -  Have experienced any arterial or venothrombotic or thromboembolic events within 6
             months prior to study treatment.

          -  Have liver cirrhosis with a Child-Pugh class B or worse or cirrhosis (any degree) and
             a history of hepatic encephalopathy or clinically meaningful ascites resulting from
             cirrhosis.

          -  The participant is pregnant prior to randomization or breastfeeding.

          -  The participant has sensory peripheral neuropathy ≥ Grade 2 (Part E only).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SMO Sarah Cannon Research Inst.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/solid-tumor/JQBA#?postal=</url>
    <description>Click here for more information about this study:A Study of LY3127804 with Ramucirumab in Participants with Advanced Solid Tumors</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced, Angiopoietin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

